Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell L… (NCT01172314) | Clinical Trial Compass
CompletedNot Applicable
Effects of Essential Amino Acid Intake on Net Protein Synthesis in Weight-losing Non-small Cell Lung Cancer Patients
United States41 participantsStarted 2010-07-13
Plain-language summary
Weight loss commonly occurs in lung cancer patients, negatively influencing their quality of life, treatment response and survival. Gains in lean body mass are difficult to achieve in cancer unless specific metabolic abnormalities are targeted. It is our hypothesis that a nutritional supplement containing a high amount of essential amino acids will target the metabolic alterations of cancer patients. Preliminary research performed in our laboratory in elderly supports this hypothesis. We hypothesize that intake of an essential amino acid nutritional supplement will positively influence protein synthesis rate in advanced non-small cell lung cancer (NSCLC) patients. Furthermore, insight in the underlying mechanism of the higher anabolic response of the essential amino acid supplement will be examined. This information will potentially enable us to formulate a supplement that is more effective than normal food intake, and that will reduce the need for muscle protein breakdown.
Who can participate
Age range40 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Recently diagnosed with Stage III (unresectable) or Stage IV lung cancer (only for the NSCLC group)
✓. Ability to sign informed consent
✓. Age 40 years and older
Exclusion criteria
✕. Previous anti-cancer therapy (e.g. radiotherapy, chemotherapy) or surgery less than 4 weeks prior to the experiment.
✕. Presence of fever within the last 3 days
✕. Established diagnosis of Diabetes Mellitus
✕. BMI \> 35 kg/m2
✕. Untreated metabolic diseases including hepatic or renal disorder
✕. Presence of acute illness or metabolically unstable chronic illness
✕. Use of long-term oral corticosteroids or short course of oral corticosteroids in the preceding month before enrollment
What they're measuring
1
Acute change in Net whole body protein synthesis rate
. Diagnosis of moderate to severe chronic airflow limitation, defined as measured forced expiratory volume in one second (FEV1) ≤ 70% of referen¬ce FEV1 (only for the healthy control group)